Heghine Khachatryan: New Insights on Thrombosis in BCR-ABL1 Negative Myeloproliferative Neoplasms
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Journal of Thrombosis and Haemostasis (JTH)’s post on LinkedIn, adding:
“New insights into thrombosis in BCR::ABL1-negative myeloproliferative neoplasms
Thrombosis remains the leading cause of morbidity and mortality in patients with Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs).
Understanding the molecular mechanisms underlying thrombotic risk is essential for improving both risk stratification and targeted therapeutic approaches.
A recent study published in the Journal of Thrombosis and Haemostasis demonstrates that dysregulation of HIF-1α–regulated and thromboinflammatory genes is associated with an increased thrombotic risk in patients with BCR::ABL1-negative MPNs.
In a cohort of 120 patients, increased expression of genes including SLC2A1 and SELP correlated with a history of thrombosis, supporting the concept that hypoxia signaling and thromboinflammation are integral components of MPN pathobiology.
These findings reinforce the growing evidence that thrombotic risk in MPN extends beyond conventional clinical predictors and is closely linked to molecular and inflammatory pathways.
Identification of such biomarkers may facilitate more precise risk assessment and contribute to the development of novel targeted therapeutic strategies.”
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Olga Morath et al., adding:
“Dysregulation of HIF-1α–regulated and thromboinflammatory genes may contribute to thrombotic risk in patients with BCR::ABL1-negative myeloproliferative neoplasms
In 120 MPN patients, SLC2A1 and SELP gene expression were independently linked to thrombosis, with higher expression in JAK2-mutated patients suggesting a JAK2–HIF pathway connection.”
Title: Dysregulation of HIF-1α–regulated and thromboinflammatory genes may contribute to thrombotic risk in patients with BCR::ABL1-negative myeloproliferative neoplasms
Authors: Olga Morath, Therese Wolfrum, Carl Crodel, Andreas Hochhaus, Thomas Ernst, Jenny Rinke
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Jun 30, 2026, 15:33Francois Delvoye: Thrombo-Inflammation and NETs May Represent the Next Therapeutic Frontier in SAH
-
Jun 30, 2026, 15:23The DETECT-VTE Study Reminds Us That VTE Doesn’t Always Look Typical – RPTH
-
Jun 30, 2026, 15:17Fayad Al-Haimus: CAEP–CanVECTOR Research Grant Backs Pulmonary Embolism Study
-
Jun 30, 2026, 15:03Hugo Ribeiro: Republished Paper Highlights Folic Acid and Iron Supplementation in Anemia
-
Jun 30, 2026, 14:49Ryan O’Keefe: Diagnostic Insights Into High-Risk Myelodysplastic Syndrome
-
Jun 30, 2026, 14:40A Patient-Centered Approach on Hormone Therapy Following Thrombosis – Thrombosis Canada
-
Jun 30, 2026, 14:32Lindsey George: Blood Study Links AAV-Derived FVIII Activity to Clinical Outcomes
-
Jun 30, 2026, 10:01Robert Lufkin: Stop Eating 3 Hours Before Bed
-
Jun 30, 2026, 09:52Kathleen Freson: Opportunities to Lead Thrombosis and Hemostasis in ISTH